Stock Fundamentals

Company Information

Company Name
NRX Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US6294442099
CIK: 0001719406
CUSIP: 629444100
Currency: USD
Full Time Employees: 29
Phone: 484 254 6134
Fiscal Year End: December
IPO Date: Dec 04, 2017
Description:

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Address:

1201 N. Market Street, Wilmington, DE, United States, 19801

Directors & Officers

Name Title Year Born
Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chairman & CEO 1957
Mr. Michael S. Abrams M.B.A. CFO & Treasurer 1970
Mr. Joseph M. Casper Chief Operating Officer 1951
Dr. Riccardo Panicucci Ph.D. Chief Manufacturing & Technology Officer 1962
Dr. Hervé Perron HDR, Ph.D. Chief Scientist 1959
Suzanne Messere Investor Relations NA
Dr. Philip T. Lavin Ph.D. Chief Methodologist 1947
Dr. Dennis K. McBride Ph.D. Chief Strategy Officer & Director 1955
Prof. Joshua C. Brown M.D., Ph.D. Chief Medical Innovation Officer NA
Mr. Glenn Tyson Chief Commercial Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 17, 2024 Jonathan C Javitt N/A Purchase 40.00K $1.17 $46.80K
Aug 30, 2023 Aaron Gorovitz N/A Purchase 3.50K $3.20 $11.20K
Aug 22, 2023 Jonathan C Javitt N/A Purchase 20.00K $3.20 $64.00K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
B Group, Inc 3.00M Mar 31, 2026 8.28% $4.74 0.00%
Vanguard Capital Management, LLC 1.16M Mar 31, 2026 3.20% $0.00 0.00%
Vanguard Group Inc 729.84K Dec 31, 2025 2.01% $0.00 36.43%
AdvisorShares Investments, LLC 420.47K Mar 31, 2026 1.16% $0.16 28.19%
Commonwealth Equity Services Inc 397.43K Mar 31, 2026 1.10% $0.00 8.40%
Geode Capital Management, LLC 310.11K Mar 31, 2026 0.86% $0.00 41.69%
Vanguard Fiduciary Trust Co 169.58K Mar 31, 2026 0.47% $0.00 0.00%
Bleakley Financial Group LLC 117.20K Mar 31, 2026 0.32% $0.00 0.00%
BlackRock Inc 99.00K Mar 31, 2026 0.27% $0.00 19.77%
State Street Corp 86.98K Mar 31, 2026 0.24% $0.00 0.00%
XTX Topco Ltd 78.73K Mar 31, 2026 0.22% $0.00 0.00%
Jane Street Group LLC 44.15K Mar 31, 2026 0.12% $0.00 15.99%
Northern Trust Corp 43.47K Mar 31, 2026 0.12% $0.00 50.17%
Headlands Technologies LLC 39.39K Mar 31, 2026 0.11% $0.01 0.00%
Global Retirement Partners, LLC. 39.30K Dec 31, 2025 0.11% $0.00 0.00%
One Wealth Management Investment & Advisory Services LLC 37.87K Dec 31, 2025 0.10% $0.11 35.30%
Chicago Partners Investment Group LLC 34.48K Mar 31, 2026 0.10% $0.00 3.17%
AXQ CAPITAL LP 33.21K Mar 31, 2026 0.09% $0.01 0.00%
Virtu Financial LLC 31.79K Mar 31, 2026 0.09% $0.00 0.00%
UBS Group AG 25.23K Mar 31, 2026 0.07% $0.00 613.03%

Shares Statistics

Shares Outstanding: 42.80M
Shares Float: 30.45M
% Insiders: 758.00%
% Institutions: 1,745.70%
Short % Float: 14.44%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 744.53K 2.35% ▲ 0.00% Apr 30, 2026
2 AdvisorShares Psychedelics ETF 632.09K 1.99% ▲ 0.00% May 29, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 324.19K 1.02% ▲ 0.00% Apr 30, 2026
4 Fidelity Extended Market Index 171.88K 0.54% ▼ 0.36% Apr 30, 2026
5 Abante Quant Value FI 88.09K 0.28% ▲ 0.00% Mar 31, 2026
6 iShares Micro-Cap ETF 65.67K 0.21% ▲ 0.00% May 29, 2026
7 Vanguard Instl Ttl Stk Mkt Idx InstlPls 62.61K 0.20% ▲ 0.00% Apr 30, 2026
8 Mandarine Global Microcap G EUR 60.00K 0.19% ▲ 20.00% Feb 28, 2026
9 Spartan Extended Market Index Pool F 35.39K 0.11% ▲ 1.81% Apr 30, 2026
10 Fidelity Series Total Market Index 34.47K 0.11% ▲ 0.00% Apr 30, 2026

Valuation Metrics

Enterprise Value: $158.79M
Trailing P/E: 0.00
Forward P/E: 34.25

Financial Highlights

Market Cap: $164.35M
EBITDA: $-17.06M
Book Value: $-0.41
Earnings/Share: $-1.04
Profit Margin: 0.00%
Operating Margin: -444.57%
ROA (TTM): -110.23%
ROE (TTM): -682.61%
Revenue (TTM): $2.29M
Revenue/Share (TTM): $0.09
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 0.31x -0.02x 2.23x -24.18x -0.01x
2024-12-31 0.15x -0.28x 7.36x -18.26x -0.27x
2023-12-31 0.36x -0.78x 2.60x -229.89x -0.31x
2022-12-31 1.66x 1.42x 0.71x -9.68x -0.26x
2021-12-31 2.74x 0.02x 0.36x -5,288.94x -0.01x
2020-12-31 0.06x -0.07x 15.88x -393.95x -0.06x
2019-12-31 0.11x 0.07x 0.08x N/A 3.96x
2018-12-31 0.05x 0.01x 0.02x N/A 8.37x
2017-12-31 5.76x 0.00x 0.00x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NRXP.US!